3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 3
2
Phase 2
2
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
245
Carcinoma, Non-Small-Cell Lung
225
Prostatic Neoplasms
113
Neoplasms
104
Multiple Myeloma
90
Neoplasm Metastasis
75
Colorectal Neoplasms
73
Parkinson Disease 4, Autosomal Dominant Lewy Body
69
Lung Neoplasms
66
Ovarian Neoplasms
61
Leukemia, Myeloid, Acute
50
Carcinoma, Hepatocellular
47
Melanoma
46
Leukemia, Lymphocytic, Chronic, B-Cell
44
Carcinoma, Renal Cell
43
Urinary Bladder Neoplasms
41
Stomach Neoplasms
41
Squamous Cell Carcinoma of Head and Neck
41
Triple Negative Breast Neoplasms
40
Recurrence
40
Brain Neoplasms
40
Myasthenia Gravis
37
Small Cell Lung Carcinoma
35
Lymphoma, Follicular
35
Nasopharyngeal Carcinoma
34
Head and Neck Neoplasms
33
Pancreatic Neoplasms
32
Rectal Neoplasms
30
Lymphoma, Large B-Cell, Diffuse
30
Colonic Neoplasms
29
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Immunonutrition Diet
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Urinary Bladder Diseases
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT05726786
2025-12-09
INCyst
Centre Hospitalier Universitaire Vaudois
Phase 3
Recruiting
232 enrolled